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We have recently reported on the outcome of autologous transplantation in the rare myelomas (IgD, IgE, IgM,
and nonsecretory [NS]) but there is no real information on the outcome of these conditions after allogeneic
transplantation. We used the European Group for Blood and Marrow Transplantation myeloma database to
compare the outcomes after allogeneic transplantation of 1354 common myelomas (IgG, IgA, and light chain
myeloma) with the outcome in 26 IgD myelomas and 52 NS myelomas. There was little difference between
common and the IgD and NS myeloma patients with respect to prognostic factors although the IgD group had
a higher beta 2 microglobulin at diagnosis, shorter time to transplantation, and more T cell depletion. IgD and
NS patients had a signiﬁcantly greater achievement of complete remission at conditioning but this did not
translate into equivalent progression-free survival and overall survival for the IgD patients although the NS
outcome was very similar to that of common myeloma. The PFS and OS of IgD, common, and NS myelomas
appear similar after allogeneic transplantation, despite a tendency for higher early relapse rate in IgD
myeloma. Allogeneic transplantation may, therefore, be an option to investigate in prospective observational
studies.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTIONedgments on page 1058.
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ty for Blood and Marrow Transplantation.There have been a number of recent reports of the
outcome of autologous transplantation for the rare mye-
lomas (IgD, IgE, IgM, and nonsecretory myeloma [NS]) [1-4].
In the largest report [1], we have suggested that IgD, IgE, and
IgM myelomas have a worse outcome after autologous
transplantation than common myelomas (IgG, IgA, and light
Table 1
Patient Characteristics at Diagnosis, Transplantation Characteristics, and Outcome Data
Characteristic Common Myelomas
(n ¼ 1354)
% Data
Available
IgD Myelomas
(n ¼ 31)
% Data
Available
NS Myelomas
(n ¼ 52)
% Data
Available
Patient Characteristics IgG 794 (55%)
IgA 275 (19%)
BJ 285 (20%)
100 IgD 26 (1.8%) 100 NS 52 (3.6%) 100
Gender
Male, % 810 (59.8%) 100 544 (71.0%) 100 33 (63.5%) 100
Age at Tx, Yr 47.0 100 44.8* 100 45.7* 100
b2m
mg/L 2.8 30.6 6.7y 38.7 2.6 30.8
Stage at diagnosis
Salmon Durie I 11.3 84.0 3.7 87.1 7.5 76.9
II 19.8 14.8 17.5
III 69.0 81.5 75.0
Graft source
BM, % 45.2 100 51.6 100 34.6 100
PB, % 54.8 48.4 65.4
Conditioning
MAC 70.1 100 67.7 100 63.5 100
RIC 29.9 32.3 36.5
Time to transplantation, mo 11.7 100 10.9 100 11.6 100
T cell depletion
No 69.1 91 51.9y 91 65.2 88
Yes e in vivo 7.8 25.9 10.9
Yes e ex vivo 14.3 11.1 21.7
Yes e both 8.8 11.1 2.2
Gender mismatch female -> male
% of all transplantations 24.4 100 29.0 100 23.1% 100
Disease response at conditioning
CR 16.3 82 28.0z 78 42.5 77
PR 62.3 52.0 45.0
No change 16.1 12.0 7.5
Relapse/progression 5.3 8.0 5.0
Use of TBI 60.3 98 61.3 100 42.0x 96
Outcome Data
CR after transplantation at 12 months
Cumulative incidence .32 92 .33 100 .34 100
Median OS, mo (95% CI) 30.6 (25.2-36.7) 16.2 (13.9-NA) 45.0 (13.2-NA)
Survival at 36 months (95% CI)
Survival .47 (.44-.50) 442 patients 38 (.24-0.61) 9 patients 54 (.41-.71) 19 patients
Median PFS, mo (95% CI) 13.6 (11.9-15.1) 16.2 (5.6-NA) 14.9 (8.0-41.4)
PFS at 36 months (95% CI) .30 (.28-.33) 296 patients .38 (.24-.61) 9 patients .34 (.23-.52) 12 patients
Tx indicates treatment; b2m, beta 2 microglobulin; BM, bone marrow; PB, peripheral blood; PR, partial response; NA, not available.
* P ¼ .020.
y P ¼ .017.
z P ¼ .001.
x P ¼ .34.
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chemotherapy (with NS having an outcome similar to the
common myelomas), although 2 other reports suggest an
outcome similar to the common myelomas for all rare my-
elomas. As allogeneic transplantation in myeloma is only
about 8.6% of all transplantations in the European Group for
Blood and Marrow Transplantation (EBMT) registry of 1997
to 2009 and rare myeloma constitutes <6% of all myeloma,
there is little information published on the outcome of
allogeneic transplantation in rare myeloma. In this study, we
used the myeloma database of the EBMT to study the
outcome of allogeneic transplantation in IgD and NS
myeloma and have compared the result with that of 1354
common myelomas.
MATERIALS AND METHODS
A retrospective study of 1437 patients with multiple myeloma who
underwent ﬁrst allogeneic transplantation from HLA-identical sibling do-
nors between 1985 and 2009 with complete data for age, sex, and type of
myeloma was undertaken. Patients with no follow-up, missing type of
conditioning regimen, missing male-female match (<1%), and missing or
combined source of cells (<2%) were also excluded. One half of the patientsunderwent transplantation after 1999. The number of patients with each
type of myeloma is shown in Table 1. Five IgM patients were identiﬁed but
not included in the analysis. Patients with IgG, IgA, and Bence Jones (BJ)
myeloma were collectively described as common myeloma. Patients with
plasma cell leukemia were analyzed in a concurrent analysis. Solitary
plasmacytoma and amyloidosis were also excluded. All patients were re-
ported to the EBMT registry using MED A (limited data set) or MED B (for
extensive data set) forms. All 1432 allografted patients (IgM excluded) were
included in the study regardless of availability of complete MED A or MED B
data. The number of patients who could be evaluated for each parameter
was noted and the proportions of evaluable patients are included in the
results. Factors known to affect transplantation outcomes from previous
EBMT studies were also analyzed [5]. Response criteria were those used by
the centers that were in current use at the time of reporting. On account of
differences in follow-up, the analysis of outcomes is restricted (artiﬁcial
censoring) to the ﬁrst 4 years after transplantation, a ﬁgure equivalent to the
lowest median follow-up for the 3 groups.
Statistical Methods
Overall survival (OS) and progression-free survival (PFS) were deﬁned,
respectively, as time from transplantation to death and to the ﬁrst event
among relapse, progression, or death; observations were censored at the
time of last follow-up in case of no failure. OS and PFS curves were produced
using the Kaplan-Meier estimator. PFS curves were compared by the log-
rank test, whereas for OS that presented crossing curves, we tested the
Figure 1. (A) Shows overall survival, (B) shows relapsed/progression-free survival, (C) shows relapse/progression, and (D) shows nonrelapse progression mortality for
common, IgD, and NS myeloma. All differences are nonsigniﬁcant.
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meaningful in these situations, and the log-rank test is not suitable to detect
differences at a speciﬁc point in time); this was done applying themethod of
the “cloglog” transformation proposed by Klein et al. [6]. The other time-to-
event endpoints (relapse/progression incidence, nonrelapse mortality
[NRM], achievement of complete remission [CR], occurrence of graft-versus-
host disease [GVHD], and engraftment) were analyzed in a competing risks
framework, applying the proper nonparametric estimator of the crude cu-
mulative incidence curves and the Gray test for comparison [7]. Death was
considered a competing risks in all analyses (except NRM); relapse/pro-
gression was a competing risk for NRM and for CR achievement; only pa-
tients surviving at 100 days were considered to be at risk of chronic GVHD.
Conversely, acute GVHDwas analyzed until 100 days. For the comparisons of
characteristics in groups, the standard nonparametric tests were applied
(chi-squared or Fisher exact test for categorical variables, Mann-Whitney/
Kruskal-Wallis Test for continuous variables).
RESULTS
The patient characteristics at diagnosis are shown in
Table 1 with percentage availability of results for eachvariable shown. There was little difference between the
groups in respect of most variables (including albumin, cal-
cium, creatinine, and hemoglobin; 39 g/L, 2.21 mmol/L, 71
mmol/L, and 9.0 g/dL, respectively, median values for the IgD
patients) except that the IgD group had signiﬁcantly higher
beta 2 microglobulin (P ¼ .02 overall). All 23 IgD patients
reported had l light chains. The lower median age of IgD and
NS patients (P ¼ .02 compared to common) would seem
insufﬁcient to be of biological importance.Transplantation-related Variables
Table 1 also shows transplantation-related variables,
including graft source, intensity of conditioning, T cell
depletion and type, the proportion of female donor to male
recipient matches, disease response, and use of total body
irradiation (TBI) in conditioning. Percentage availability is
shown where appropriate. The most commonly used of the
Figure 2. (A) Shows acute graft-versus-host disease and (B) shows chronic graft-versus-host disease for common, IgD, and NS myeloma. All differences are
nonsigniﬁcant.
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melphalan, which account for 47% of reported regimens.
There was less use of T cell depletion in the IgD group and
differences in the type of T cell depletion used, but the sub-
groups (in vivo, in vitro, or combined depletion) were too
small for separate analysis. IgD and NS patients also achieved
a signiﬁcantly higher proportion of CR before transplantation
(P ¼ .001). Response in NS myeloma was as deﬁned by
reporting institutions. There was no difference in time to
engraftment of leukocytes, neutrophils, and platelets be-
tween groups.
Transplantation Outcomes
In a preparatory analysis, the OS and PFS of the IgG, IgA,
and BJ myelomas were compared. Although the IgA group
appeared to have had better outcomes than the IgG or BJ
groups (OS median: 43 months versus 28 months and 26
months, respectively; PFS median: 17 months versus 12
months and 14 months, respectively), these differences do
not reach statistical signiﬁcance, even comparing IgA versus
the other 2 groups combined (P values .096 and .249,
respectively, for OS and PFS). Thus, the control group of usual
myelomas was considered to be homogeneous.
Figure 1A-D show the data for OS, PFS, relapse/progres-
sion, and NRM, respectively. Although there were no signif-
icant differences in the achievement of CR between groups in
Figure 1A, it appears that the patients with IgD myelomas
may have a worse performance than the common and NS
patients. Overall survival was 16.2 months (95% conﬁdence
interval [CI], 13.9 to >48), 30.6 (95% CI, 25.2 to 36.7), and 45
(95% CI, 13.2 to >48) respectively. However, statistical
assessment of differences is difﬁcult because of the IgD and
common curves crossing in 2 points, whereas comparison at
36 months using the clog-log method shows a trend for
poorer survival (P ¼ .149) but with the small numbers sur-
viving at 3 years, the comparison of IgD and NS is nonsig-
niﬁcant. Thus, there may be little difference in the outcome
of rare and common myelomas.
Figure 1B shows the PFS for the 3 groups. PFS for common
was 13.6 months (95% CI, 11.9 to 15.1), for IgD it was 16.2
months (95% CI, 5.6 to >48), and for NS it was 14.9 months
(95% CI, 8.0 to 41.4). Although the values for OS and PFS are
similar for the IgD group, it should be noted that the conﬁ-
dence intervals for both OS and PFS for this group are verywide because of the small number of cases. Figure 1C and D
show IgD myelomas appear to have a higher rate of early
relapse/progression (but about the same at 36 months) and
correspondingly a lower NRM than NS (and common)
myeloma; but, again it is about the same at 36 months and
signiﬁcance is not reached. Thus, it appears there is no
signiﬁcant difference between the groups.
GVHD
Figure 2A and B show the incidence of acute and chronic
GVHD. Ninety-three percent of cases were evaluable for
acute GVHD and 99% for chronic GVHD. There is no difference
between the groups (Gray test, P ¼ .787 and P ¼ .245,
respectively).
Myeloablative versus Reduced-intensity Conditioning
Only 10 patients in the IgD/NS subpopulation had
reduced-intensity conditioning (RIC); too low for meaningful
statistical analysis by usual methods. As the majority of pa-
tients had myeloablative (MAC), the NRM overall is high.
Nevertheless, we looked for any sign of differences
depending on RIC or MAC (interactions); the interaction
terms were highly nonsigniﬁcant, suggesting that they are
not affected by the inclusion of the RIC group.
DISCUSSION
The rare myelomas have intrigued hematologists and
biochemists ever since their ﬁrst identiﬁcation. One factor
that has consistently been noted (with occasional excep-
tions) is the poor survival for patients with rare myelomas
compared with patients with common myelomas with con-
ventional therapy. Compared with the reported survival for
IgDmyeloma,Wechalekar et al. [2], found survival was better
for 11 IgD patients who received autologous transplantation,
but survival was inferior to common myeloma. Sharma et al.
[3] (17 patients) and Reece et al. [4] (36 patients) showed
considerable improvement in survival after autologous
transplantation with OS similar to common myeloma. In our
series [1], consisting of 379 IgD patients, OS after autologous
transplantation was signiﬁcantly less than for common
myeloma patients (43.5 months and 62.3 months, respec-
tively). This overall improvement in survival for all myelomas
after autologous transplantation, still keeping a clear differ-
ence between rare and common myelomas, was obtained
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may account for part of this apparent improvement in sur-
vival for rare myeloma due to autologous transplantation. In
contrast, little information has been published on the
outcome of allogeneic transplantation in rare myelomas.
In the present study of allogeneic transplantation, per-
formed retrospectively with mainly MAC conditioning and
HLA-identical sibling donors andmostly before the use of the
novel drugs (proteosome inhibitors and immunomodulatory
drugs), the difference in outcome between common and rare
myelomas is not obvious. The small proportion of patients
undergoing RIC allogeneic conditioning is a reﬂection of the
period of data collection, which ended in 2010 when RIC
allogeneic transplantations started to be performed much
more frequently. Although there is a tendency for an early
higher relapse rate in rare myelomas, it is no longer signiﬁ-
cantly different at 36 months. The PFS is similar. OS tends to
be somewhat inferior in the beginning, but at 36 months
there is no difference. Although numbers are small, the lack
of signiﬁcant difference could be an indication that alloge-
neic transplantation partly overcomes the poorer prognosis
in rare myelomas, also seen in allogeneic transplantation of
patients with other poor prognosis parameters [8,9]. In a
separate analysis (not shown), adding data from the 5 IgM
patients to the IgD group gave very similar results. As this
survey covers a wide time period, it seems probable that the
improved outcome measures noted in successive time co-
horts [10] and conﬁrmed in recent randomized clinical trials
[11,12] could apply to the rare myelomas, but the number of
cases is too small for this analysis.
It should be noted that NS myeloma should be considered
separate from IgD myeloma. Better techniques are showing
that only a small proportion of NSmyeloma cannot be shown
to have any Ig or light chain speciﬁcity. Although monitoring
response is more difﬁcult, on account of the lack of easily
measured biomarker, OS is very similar to that for common
myelomas [1,13,14] and our study once again conﬁrms this
view.
Although conﬁning our report to patients with reasonably
complete data sets at initial reporting (consistent with our
report on autologous transplantation), follow-up reporting is
modest, resulting in truncation of the follow-up to 4 years
after transplantation. Obtaining reliable long-term follow-up
for myeloma patients has proved challenging for EBMT, but
this is being addressed for future studies. It may also account
for the unusual similarity between OS and PFS (both 16.2
months) in the IgD group, where the wide conﬁdence in-
tervals are a factor and (in an analysis not shown) there is
joining of the PFS and OS plots just before the median is
reached.
Our results highlight the difﬁculty of obtaining a mean-
ingful understanding of how to manage rare conditions such
as IgD and other rare myelomas. We suggest that allogeneictransplantation may be an effective modality in the condi-
tion, but as many of the patients were treated in the era
before the use of novel drugs, further evaluation is required.
As randomized controlled clinical trials are not practical for
this group, and although inclusion of IgD patients into poor
prognosis studies might be considered, the best approach to
understanding how to treat such patients may be through
the use of prospective observational studies, possibly after an
overall plan of management.ACKNOWLEDGMENTS
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